GRADUATE SCHOOL

Departments

Graduate School of Medicine/Graduate School of Public Health

Staff Information

Hisashi Yamanaka

MD, PhD
Graduate School of Medicine, IUHW

Profile (Career Summary)

Mar, 1980: Graduate from School of Medicine, Mie University
Feb, 1985: Post-Doctoral Fellow, Scripps Research Institute (La Jolla, CA, USA)
May, 2003: Professor, Institute of Rheumatology, School of Medicine, Tokyo Women’s Medical University
Jun, 2018: Professor, Department of Rheumatology, School of Medicine, Tokyo Women’s Medical University
Jul, 2019 to the present: Professor of Rheumatology, School of Medicine, IUHW
May, 2020 to the present: Director, Sanno Medical Center, Head of Rheumatology center.

Degree

MD, PhD (Tokyo Women’s Medical University)

Subspeciality

Internal Medicine, Rheumatology

Research Theme

Clinical researches in Rheumatology, especially of rheumatoid arthritis and gout. Establishment of Real-World Evidence using large scale disease cohort.
Establishment of clinical practice guidelines based on EBM.

Contributions

Major publications
  1. Yamanaka H, Tanaka E, Nakajima A, et al. A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today's treatment options. Mod Rheumatol. 2020 Jan;30(1):1-6.
  2. Yamanaka H, Tamaki S, Ide Y, K et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018 Feb;77(2):270-276
  3. Yamanaka H, Askling J, Berglind N, et al. Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open. 2017 Oct 10;3(2):e000498.
  4. Yamanaka H, Nagaoka S, Lee SK, et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Mod Rheumatol. 2016 Sep;26(5):651-61.
  5. Yamanaka H, Ishiguro N, Takeuchi T, et al. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology (Oxford). 2014 May;53(5):904-13
  6. Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000 Apr;43(4):852-8.
  7. Yamanaka H, Willis EH, Carson DA. Human autoantibodies to poly (adenosinediphosphate-ribose) polymerase recognize cross-reactive epitopes associated with the catalytic site of the enzyme. J Clin Invest. 1989 Jan;83(1):180-6.
  8. Yamanaka H, Penning CA, Willis EH, et al. Characterization of human poly (ADP-ribose) polymerase with autoantibodies. J Biol Chem. 263(8):3879-3883, 1988.
  9. Yamanaka H, Kubota M, Carson DA. Synergistic inhibition of polyamine synthesis and growth by difluoromethylornithine plus methylthioadenosine in methylthioadenosine phosphorylase- deficient murine lymphoma cells. Cancer Res. 1987 Apr 1;47(7):1771-4.
  10. Yamanaka H, Willis EH, Penning CA, et al. Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase. J Clin Invest. 1987 Sep;80(3):900-4.

Major awards

  • 2000: Society award of Japanese Society of Gout and Uric & Nucleic Acids
  • 2003: Award for Rheumatology Clinical Medicine from Japan Rheumatism Foundation
  • 2012: Society award of Japan College of Rheumatology